Sponsors poured $3B into AI to fix trial enrollment and 80% still miss deadlines. Three clinical-ops voices on why...

Eli Lilly gave 1,000+ hospitals five days to submit claims data or lose 340B discounts—exposing how pharma giants shift...

Iopofosine I-131 achieves 79% response rate in BTKi-resistant Waldenström Macroglobulinemia patients, with median response duration of 16 months.

Voyager's VY1706 gene therapy targeting tau protein receives FDA clearance, with first-in-human dosing expected in late 2026 for early...

Multi-arm multi-stage platform trials could cut neurodegenerative drug timelines in half—but FDA adaptive design rules haven't caught up with...

Immatics' Anzu-cel demonstrates 56% response rate in melanoma Phase 1b, with 67% efficacy in uveal melanoma and median duration...

Daraxonrasib halves death risk in Phase 3 pancreatic cancer trial, doubling median overall survival in previously treated metastatic disease.

Apalutamide plus hormone therapy reduced metastasis risk by 20% in high-risk prostate cancer, with nearly ninefold improvement in pathologic...

FDA accepts NDA for Roche's Giredestrant in early-stage breast cancer, showing 30% reduction in recurrence or death versus standard...

A Vanguard Publications Q&A with Naomi, eClinical Solutions.